Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 10/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14263432 | 0.94 | CACNA1H (0.54) | CACNA1HTRPV1MEN1KMT2A | |
| SCHEMBL8217835 | 0.93 | TRPV1 (0.55) | TRPV1USP30 | |
| SCHEMBL8205482 | 0.88 | CACNA1H (0.55) | CACNA1HTRPV1 | |
| SCHEMBL8212694 | 0.87 | TRPV1 (0.61) | CACNA1HTRPV1USP30 | |
| SCHEMBL8209853 | 0.86 | TRPV1 (0.55) | CACNA1HTRPV1 | |
| SCHEMBL8210218 | 0.86 | CACNA1H (0.46) | CACNA1HTRPV1MEN1KMT2A | |
| SCHEMBL8218916 | 0.86 | CACNA1H (0.57) | CACNA1HTRPV1 | |
| SCHEMBL8210646 | 0.86 | GPR119 (0.52) | CACNA1H | |
| SCHEMBL8202849 | 0.86 | CACNA1H (0.49) | CACNA1HTRPV1MEN1KMT2A | |
| SCHEMBL8227841 | 0.85 | TRPV1 (0.55) | CACNA1HTRPV1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| WO-2008033460-A2 | TREATING PAIN, DIABETES, AND LIPID METABOLISM DISORDERS | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, CES1, ZDHHC20 | CACNA1H 2829/4885TRPV1 438/4885USP30 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.